Lys-Glu

What is Lys-Glu?

A dipeptide studied in thymic/immune bioregulator research with limited broader clinical validation.

This profile is educational. It organizes publicly discussed research context for Lys-Glu and related naming aliases — it is not a treatment guide.

Proposed mechanism

Proposed immune-cell gene-expression modulation in short-peptide bioregulator models.

Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.

Current research notes

Human evidence grade: Insufficient evidence summarized

Preclinical evidence grade: Early-stage human research

Vilon (KE) is part of the Khavinson peptide family. Evidence quality varies; treat marketing claims cautiously.

Key uncertainties

• Human clinical benefit

Research areas being studied

• Immunology research
• Bioregulator peptides

Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.

Safety & side-effect notes

Reported or discussed adverse effects

• Insufficient systematic human data

Additional risks & considerations

• Unproven immune claims

Regulatory status

Research-stage

Regulatory framing here is educational and can lag policy changes. Check official sources for current status.

Frequently asked questions

References & sources

• Khavinson VK et al. (2002). Vilon (KE) peptide research — Bull Exp Biol Med. Evidence type: review.